First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations
- Author(s)
- Zhou, C; Shu, CA; Greillier, L; Liu, G; John, T; Xing, L; Kowalski, D; Memmott, RM; Yazici, O; Sun, M; Pons-Tostivint, E; Fan, Y; Fernandez-Hinojal, G; Shum, E; Wang, M; Bertolini, F; Camidge, DR; Zhou, C; Doucet, L; Hong, Q; Fang, J; Huang, D; Jin, B; Yu, Y; Antonuzzo, L; Moro-Sibilot, D; Bennouna, J; de Castro, G, Jr; Zheng, L; Heymach, JV; WU-KONG28 Investigators;
- Details
- Publication Year 2026-08-20,Volume 395,Issue #8,Page 765-775
- Journal Title
- New England Journal of Medicine
- Publication Type
- Research article
- Abstract
- BACKGROUND: Sunvozertinib received accelerated approval for use in later lines of therapy for patients with advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations. Data are needed on the efficacy and safety of sunvozertinib as a first-line treatment for NSCLC. METHODS: In this phase 3, international trial, we randomly assigned, in a 1:1 ratio, patients with advanced nonsquamous NSCLC with EGFR exon 20 insertions to receive sunvozertinib or chemotherapy (carboplatin-pemetrexed). The primary end point was progression-free survival as assessed by blinded independent central review. Crossover to the sunvozertinib group was allowed after disease progression was confirmed. Secondary end points included overall survival, investigator-assessed progression-free survival, objective response (complete or partial response), change in tumor size, and duration of response. RESULTS: A total of 324 patients were randomly assigned to receive sunvozertinib (163 patients) or chemotherapy (161 patients). Treatment with sunvozertinib led to significantly longer median progression-free survival than chemotherapy (10.3 vs. 7.5 months; hazard ratio for disease progression or death, 0.65; 95% confidence interval, 0.50 to 0.85; P<0.001). At 12 months, progression-free survival was reported in 46.1% of the patients in the sunvozertinib group and in 26.7% of those in the chemotherapy group; the data for overall survival were immature (38.9% maturity). The percentage of patients with an objective response was 58.9% in the sunvozertinib group and 31.1% in the chemotherapy group; the median best percentage change in tumor size was -42.1% and -24.7% respectively, and the median duration of response was 11.2 and 7.1 months. Grade 3 or higher adverse events were reported in 75.5% of the patients in the sunvozertinib group and in 56.7% of those in the chemotherapy group. In the sunvozertinib group, the most common adverse events of grade 3 or higher included increased serum creatine kinase levels, diarrhea, and anemia. No deaths were attributed to adverse events considered by the investigators to be related to sunvozertinib. CONCLUSIONS: The efficacy of sunvozertinib was superior to that of chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertions. (Funded by Dizal Pharmaceuticals; WU-KONG28 ClinicalTrials.gov number, NCT05668988.).
- Publisher
- Massachusetts Medical Society
- Keywords
- Humans; *Lung Neoplasms/drug therapy/genetics/mortality; *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics/mortality; ErbB Receptors/genetics; Exons; Female; Aged; Middle Aged; Male; Progression-Free Survival; *Mutagenesis, Insertional; Adult; Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects; Carboplatin/therapeutic use; Pemetrexed/therapeutic use/administration & dosage; Kaplan-Meier Estimate; *Antineoplastic Agents/therapeutic use/adverse effects; Aged, 80 and over; Acrylamides; Pyrrolidines
- Department(s)
- Medical Oncology
- Publisher's Version
- https://doi.org/10.1056/NEJMoa2604461
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2026-06-04 04:32:21
Last Modified: 2026-09-16 04:38:40